Expect FDA transparency recommendations on NDA/BLA disclosures early next year
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration’s transparency task force expects to release draft recommendations in early 2010 on the types of medical product application information that should be disclosed by the agency and under what circumstances.